These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 23990501)

  • 1. 2012 AAPS National Biotech Conference Open Forum: a perspective on the current state of immunogenicity prediction and risk management.
    Rajadhyaksha M; Subramanyam M; Rup B
    AAPS J; 2013 Oct; 15(4):1155-9. PubMed ID: 23990501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conference report: Bioanalysis highlights from the 2012 American Association of Pharmaceutical Scientists National Biotechnology Conference.
    Crisino RM; Geist B; Li J
    Bioanalysis; 2012 Sep; 4(17):2103-7. PubMed ID: 23013391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioanalysis-related highlights from the 2011 AAPS National Biotechnology Conference.
    Crisino RM; Dulanto B
    Bioanalysis; 2011 Aug; 3(16):1809-14. PubMed ID: 21877889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conference report: hot topics in antibody-drug conjugate development.
    Thudium K; Bilic S
    Bioanalysis; 2013 Dec; 5(24):2989-93. PubMed ID: 24320125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How Close Are We to Profiling Immunogenicity Risk Using In Silico Algorithms and In Vitro Methods?: an Industry Perspective.
    Gokemeijer J; Jawa V; Mitra-Kaushik S
    AAPS J; 2017 Nov; 19(6):1587-1592. PubMed ID: 28971356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New FDA draft guidance on immunogenicity.
    Parenky A; Myler H; Amaravadi L; Bechtold-Peters K; Rosenberg A; Kirshner S; Quarmby V
    AAPS J; 2014 May; 16(3):499-503. PubMed ID: 24682766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality.
    Hock MB; Thudium KE; Carrasco-Triguero M; Schwabe NF
    AAPS J; 2015 Jan; 17(1):35-43. PubMed ID: 25380723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing unwanted immunogenicity of biologicals.
    Deehan M; Garcês S; Kramer D; Baker MP; Rat D; Roettger Y; Kromminga A
    Autoimmun Rev; 2015 Jul; 14(7):569-74. PubMed ID: 25742758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current challenges in assessing immunogenicity.
    Shankar G
    Bioanalysis; 2019 Sep; 11(17):1543-1546. PubMed ID: 31617390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).
    Foffi G; Pastore A; Piazza F; Temussi PA
    Phys Biol; 2013 Aug; 10(4):040301. PubMed ID: 23912807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk mitigation strategies for viral contamination of biotechnology products: consideration of best practices.
    Rosenberg AS; Cherney B; Brorson K; Clouse K; Kozlowski S; Hughes P; Friedman R
    PDA J Pharm Sci Technol; 2011; 65(6):563-7. PubMed ID: 22294578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Report on the AAPS Immunogenicity Guidance Forum.
    Myler H; Gorovits B; Phillips K; Devanarayan V; Clements-Egan A; Gunn GR; Kirshner S; DeSilva B; Shah VP
    AAPS J; 2019 Apr; 21(4):55. PubMed ID: 30993501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates: May 24, 2012, San Diego, CA.
    Thudium K; Bilic S; Leipold D; Mallet W; Kaur S; Meibohm B; Erickson H; Tibbitts J; Zhao H; Gupta M
    MAbs; 2013; 5(1):5-12. PubMed ID: 23255090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Taking immunogenicity assessment of therapeutic proteins to the next level.
    Büttel IC; Chamberlain P; Chowers Y; Ehmann F; Greinacher A; Jefferis R; Kramer D; Kropshofer H; Lloyd P; Lubiniecki A; Krause R; Mire-Sluis A; Platts-Mills T; Ragheb JA; Reipert BM; Schellekens H; Seitz R; Stas P; Subramanyam M; Thorpe R; Trouvin JH; Weise M; Windisch J; Schneider CK
    Biologicals; 2011 Mar; 39(2):100-9. PubMed ID: 21353596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementing a Clinical Immunogenicity Strategy using Preclinical Risk Assessment Outputs.
    Jawa V; Maamary J; Swanson M; Zhang S; Montgomery D
    J Pharm Sci; 2022 Apr; 111(4):960-969. PubMed ID: 35122828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AAPP meeting report: Navigating the biotechnology revolution. Report on the 9th National Conference of the American Academy of Pharmaceutical Physicians (AAPP). San Diego, California, October 28-30, 2002.
    Int J Clin Pharmacol Ther; 2003 Feb; 41(2):83-94. PubMed ID: 12607631
    [No Abstract]   [Full Text] [Related]  

  • 19. Perspectives on the draft ICH-M10 guidance: an interview with Boris Gorovits.
    Gorovits B
    Bioanalysis; 2019 Aug; 11(15):1383-1385. PubMed ID: 31490105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Creating a Holistic Extractables and Leachables (E&L) Program for Biotechnology Products.
    Li K; Rogers G; Nashed-Samuel Y; Lee H; Mire-Sluis A; Cherney B; Forster R; Yeh P; Markovic I
    PDA J Pharm Sci Technol; 2015; 69(5):590-619. PubMed ID: 26429108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.